KR100596732B1 - 푸마르산과 카르니틴 및 아미노산과의 복염, 및 이를함유하는 건강 보조식품, 식이성 보충식 및 약물 - Google Patents
푸마르산과 카르니틴 및 아미노산과의 복염, 및 이를함유하는 건강 보조식품, 식이성 보충식 및 약물 Download PDFInfo
- Publication number
- KR100596732B1 KR100596732B1 KR1020027016899A KR20027016899A KR100596732B1 KR 100596732 B1 KR100596732 B1 KR 100596732B1 KR 1020027016899 A KR1020027016899 A KR 1020027016899A KR 20027016899 A KR20027016899 A KR 20027016899A KR 100596732 B1 KR100596732 B1 KR 100596732B1
- Authority
- KR
- South Korea
- Prior art keywords
- carnitine
- fumarate
- isovaleryl
- creatine
- acid
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title claims abstract description 78
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title claims abstract description 62
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 36
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 17
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title claims abstract description 6
- 150000003839 salts Chemical class 0.000 title claims description 16
- 239000001530 fumaric acid Substances 0.000 title abstract description 16
- 229960004203 carnitine Drugs 0.000 title description 4
- 235000005550 amino acid supplement Nutrition 0.000 title 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims abstract description 26
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 61
- 229960003624 creatine Drugs 0.000 claims description 30
- 239000006046 creatine Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 14
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 12
- 229960003646 lysine Drugs 0.000 claims description 12
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960003121 arginine Drugs 0.000 claims description 9
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 8
- 229960003104 ornithine Drugs 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- -1 isovaleryl Chemical group 0.000 claims description 7
- 210000002027 skeletal muscle Anatomy 0.000 claims description 7
- SIMGSNQBUQJZQP-MGVJIHIJSA-N (e)-but-2-enedioic acid;(2s)-2,5-diaminopentanoic acid Chemical compound OC(=O)\C=C\C(O)=O.NCCC[C@H](N)C(O)=O SIMGSNQBUQJZQP-MGVJIHIJSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 4
- 208000029578 Muscle disease Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000001055 chewing effect Effects 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000017854 proteolysis Effects 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 abstract description 4
- 230000009977 dual effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101100001794 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aps-2 gene Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004826 creatine monohydrate Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- VUJGONMDLUDXIA-UTONKHPSSA-N C(C=CC(=O)O)(=O)O.C(CC(C)C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O Chemical compound C(C=CC(=O)O)(=O)O.C(CC(C)C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O VUJGONMDLUDXIA-UTONKHPSSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101000985498 Mus musculus Hermansky-Pudlak syndrome 4 protein homolog Proteins 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HNSUOMBUJRUZHJ-REVJHSINSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-REVJHSINSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 210000001189 slow twitch fiber Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/02—Monosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fodder In General (AREA)
Abstract
Description
화합물 | 중량 증가율% | 외관 |
L-카르니틴 내염 | 19 | 조해성 |
이소발레릴 L-카르니틴 내염 | 20 | 조해성 |
무수 크레아틴 | 3 | 유동성 |
실시예 1 화합물(BS/231) | 0.18 | 변화 없음 |
실시예 2 화합물(BS/232) | 0.19 | 변화 없음 |
실시예 3 화합물(BS/238) | 0.16 | 변화 없음 |
Claims (9)
- 제 1 항에 있어서, 하기의 화합물들로 이루어진 그룹 중에서 선택되는 푸마레이트:-L-카르니틴 및 크레아틴 푸마레이트;-이소발레릴 L-카르니틴 및 크레아틴 푸마레이트;-L-카르니틴 및 오르니틴 푸마레이트;-이소발레릴 L-카르니틴 및 오르니틴 푸마레이트;-L-카르니틴 및 리신 푸마레이트;-이소발레릴 L-카르니틴 및 리신 푸마레이트;-L-카르니틴 및 아르기닌 푸마레이트;-이소발레릴 L-카르니틴 및 아르기닌 푸마레이트;-L-카르니틴 및 히스티딘 푸마레이트; 및-이소발레릴 L-카르니틴 및 히스티딘 푸마레이트.
- 유효 성분으로서 상기 제 1 항에 청구된 화학식 I의 푸마레이트 및 약리학적으로 허용 가능한 부형제를 포함하는 조성물.
- 제 3 항에 있어서, 산화방지제, 조효소 및 광물성 물질 중에서 선택된 하나 이상의 다른 성분을 또한 포함하는 조성물.
- 제 3 항에 있어서, 정제, 츄잉정, 환제, 트로키제, 로젠지, 캡슐, 과립 또는 분말의 형태인 조성물.
- 제 3 항에 있어서, 내염으로서 50 내지 2000 ㎎의 L-카르니틴 또는 이소발레릴 L-카르니틴을 함유하는 화학식 I의 푸마레이트를 유효 성분으로서 포함하는 단위 투여형의 조성물.
- 제 3 항 내지 제 6 항 중에서 선택된 어느 한 항에 있어서, 건강 보조식품 또는 식이성 보충식으로 사용하기 위한 조성물.
- 제 3 항 내지 제 6 항 중에서 선택된 어느 한 항에 있어서, 사료용 보충식으로서 수의학적으로 사용하기 위한 조성물.
- 제 3 항 내지 제 6 항 중에서 선택된 어느 한 항에 있어서, 근육질환과 알쯔하이머성 질환의 치료용, 및 간, 골격근 및 심경근의 단백질분해로 야기되는 간질환, 근육질환 및 심장질환의 예방용 약물로 사용하기 위한 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2000RM000322A IT1317042B1 (it) | 2000-06-14 | 2000-06-14 | Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono. |
ITRM2000A000322 | 2000-06-14 | ||
PCT/IT2001/000199 WO2001096281A1 (en) | 2000-06-14 | 2001-04-24 | Double salts of fumaric acid with a carnitine and an amino acid and food supplements, dietary supplements and drugs containing same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030017536A KR20030017536A (ko) | 2003-03-03 |
KR100596732B1 true KR100596732B1 (ko) | 2006-07-04 |
Family
ID=11454785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027016899A KR100596732B1 (ko) | 2000-06-14 | 2001-04-24 | 푸마르산과 카르니틴 및 아미노산과의 복염, 및 이를함유하는 건강 보조식품, 식이성 보충식 및 약물 |
Country Status (20)
Country | Link |
---|---|
US (1) | US6730693B2 (ko) |
EP (1) | EP1289931B1 (ko) |
JP (1) | JP4430301B2 (ko) |
KR (1) | KR100596732B1 (ko) |
CN (1) | CN1326832C (ko) |
AT (1) | ATE286016T1 (ko) |
AU (1) | AU783291B2 (ko) |
BR (1) | BR0111579A (ko) |
CA (1) | CA2412055C (ko) |
CZ (1) | CZ302371B6 (ko) |
DE (1) | DE60108122T2 (ko) |
DK (1) | DK1289931T3 (ko) |
ES (1) | ES2233635T3 (ko) |
HK (1) | HK1056549A1 (ko) |
HU (1) | HU228837B1 (ko) |
IT (1) | IT1317042B1 (ko) |
MX (1) | MXPA02012265A (ko) |
PL (1) | PL203876B1 (ko) |
PT (1) | PT1289931E (ko) |
WO (1) | WO2001096281A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2801354T (pt) * | 2004-10-08 | 2017-06-05 | Forward Pharma As | Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico |
EP1915334A2 (en) * | 2005-07-07 | 2008-04-30 | Aditech Pharma AB | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
CN101209975B (zh) * | 2006-12-29 | 2010-12-01 | 沈阳科硕营养科技有限公司 | 左旋肉碱富马酸钙及其制备方法与用途 |
UA112975C2 (uk) | 2009-01-09 | 2016-11-25 | Форвард Фарма А/С | Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
SG10201707543PA (en) | 2013-03-14 | 2017-11-29 | Alkermes Pharma Ireland Ltd | Prodrugs of fumarates and their use in treating various deseases |
CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0150688B1 (en) * | 1983-12-28 | 1987-04-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same |
FR2635264B1 (fr) | 1988-08-12 | 1992-02-28 | Bellon Labor Sa Roger | Compositions pharmaceutiques et/ou dietetiques contenant de la l-carnitine et de la l-lysine |
IT1245699B (it) * | 1991-05-29 | 1994-10-14 | Sigma Tau Ind Farmaceuti | Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi |
US5994581A (en) * | 1998-03-09 | 1999-11-30 | Amt Labs, Inc. | Carnitine creatinate |
-
2000
- 2000-06-14 IT IT2000RM000322A patent/IT1317042B1/it active
-
2001
- 2001-04-24 US US10/297,843 patent/US6730693B2/en not_active Expired - Lifetime
- 2001-04-24 JP JP2002510425A patent/JP4430301B2/ja not_active Expired - Lifetime
- 2001-04-24 AU AU60603/01A patent/AU783291B2/en not_active Expired
- 2001-04-24 EP EP01934310A patent/EP1289931B1/en not_active Expired - Lifetime
- 2001-04-24 CN CNB018111092A patent/CN1326832C/zh not_active Expired - Lifetime
- 2001-04-24 AT AT01934310T patent/ATE286016T1/de active
- 2001-04-24 CA CA002412055A patent/CA2412055C/en not_active Expired - Lifetime
- 2001-04-24 WO PCT/IT2001/000199 patent/WO2001096281A1/en active IP Right Grant
- 2001-04-24 ES ES01934310T patent/ES2233635T3/es not_active Expired - Lifetime
- 2001-04-24 MX MXPA02012265A patent/MXPA02012265A/es active IP Right Grant
- 2001-04-24 KR KR1020027016899A patent/KR100596732B1/ko active IP Right Grant
- 2001-04-24 PL PL363511A patent/PL203876B1/pl unknown
- 2001-04-24 PT PT01934310T patent/PT1289931E/pt unknown
- 2001-04-24 HU HU0301568A patent/HU228837B1/hu unknown
- 2001-04-24 DK DK01934310T patent/DK1289931T3/da active
- 2001-04-24 DE DE60108122T patent/DE60108122T2/de not_active Expired - Lifetime
- 2001-04-24 BR BR0111579-0A patent/BR0111579A/pt not_active Application Discontinuation
- 2001-04-24 CZ CZ20023949A patent/CZ302371B6/cs not_active IP Right Cessation
-
2003
- 2003-12-11 HK HK03109000A patent/HK1056549A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2001096281A1 (en) | 2001-12-20 |
ITRM20000322A1 (it) | 2001-12-14 |
AU6060301A (en) | 2001-12-24 |
KR20030017536A (ko) | 2003-03-03 |
US20030171417A1 (en) | 2003-09-11 |
HUP0301568A3 (en) | 2004-12-28 |
DE60108122D1 (de) | 2005-02-03 |
DE60108122T2 (de) | 2005-12-29 |
EP1289931A1 (en) | 2003-03-12 |
PL363511A1 (en) | 2004-11-29 |
PT1289931E (pt) | 2005-03-31 |
CN1436166A (zh) | 2003-08-13 |
JP4430301B2 (ja) | 2010-03-10 |
AU783291B2 (en) | 2005-10-13 |
EP1289931B1 (en) | 2004-12-29 |
CZ20023949A3 (cs) | 2003-04-16 |
ITRM20000322A0 (it) | 2000-06-14 |
CN1326832C (zh) | 2007-07-18 |
CA2412055C (en) | 2009-02-03 |
ATE286016T1 (de) | 2005-01-15 |
JP2004503521A (ja) | 2004-02-05 |
PL203876B1 (pl) | 2009-11-30 |
ES2233635T3 (es) | 2005-06-16 |
HK1056549A1 (en) | 2004-02-20 |
CZ302371B6 (cs) | 2011-04-13 |
US6730693B2 (en) | 2004-05-04 |
IT1317042B1 (it) | 2003-05-26 |
HU228837B1 (en) | 2013-06-28 |
HUP0301568A2 (hu) | 2003-08-28 |
MXPA02012265A (es) | 2004-02-27 |
BR0111579A (pt) | 2003-03-18 |
CA2412055A1 (en) | 2001-12-20 |
DK1289931T3 (da) | 2005-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100596732B1 (ko) | 푸마르산과 카르니틴 및 아미노산과의 복염, 및 이를함유하는 건강 보조식품, 식이성 보충식 및 약물 | |
EP1292570B1 (en) | Creatine salt having enhanced nutritional and therapeutic efficacy and compositions containing same | |
SK17292002A3 (sk) | Doplnky potravy, doplnky výživy a lieky obsahujúce podvojné soli kyseliny fumárovej s karnitínom a aminokyselinou | |
CA2453516C (en) | Alpha-ketoglutarates of l-carnitine and alkanoyl l-carnitine and compositions thereof | |
EP0971879B1 (en) | Solid compositions suitable for oral administration comprising l-carnitine and alkanoyl-l-carnitine magnesium tartrate | |
EP1330428B1 (en) | Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride | |
US6653504B1 (en) | Non-hygroscopic salts of active ingredients having therapeutical and/or nutritional activities and orally administrable compositions containing same | |
CA2285380C (en) | Solid compositions suitable for oral administration comprising non hygroscopic salts of l-carnitine and alkanoyl-l-carnitine with 2-amino-ethanesulfonic acid | |
AU2001295893A1 (en) | Solid compositions suitable for oral administration containing non-hygroscopic salts of L-carnitine and the alkanoyl L-carnitines with taurine chloride and glycine chloride | |
EP1093451B1 (en) | Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and alkanoyl l-carnitines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130612 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140612 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150609 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160616 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170614 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180614 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190614 Year of fee payment: 14 |